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What is known about this topic? 
 
 Exome sequencing increases the diagnostic yield over and above standard 
investigations in the assessment of congenital anomalies but is not yet routinely 
performed in clinical practice. 
 There is a paucity of guidance for clinicians and an urgent need to identify the 
clinical application of exome sequencing and the appropriate pre- and post-test 
counselling in the perinatal setting. 
 
What this study adds:  
 Provides information about the potential clinical utility of exome sequencing in the 
perinatal setting  
 The prenatal and early postnatal application of exome sequencing are explored 
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ABSTRACT 
Major congenital anomalies are often associated with perinatal mortality, long-term 
morbidity and prolonged hospitalisation.  Prenatal ultrasound remains the principle 
diagnostic test for many anomalies but despite this up to one third are only identified in the 
neonatal period.  The primary step in determining underlying aetiology is to define 
accurately the phenotype by recognition of dysmorphology (both prenatally and 
postnatally).  The potential introduction of Next Generation Sequencing, primarily through 
exome sequencing into perinatal practice may improve the pathologic diagnostic yield.  
However, clinicians must understand both the benefit and potential harms of this 
technology in facilitating the discovery of relevant pathogenic variants in the diagnosis and 
management of congenital malformations.  
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INTRODUCTION 
Congenital structural anomalies complicate ~2% of pregnancies (20 per 1000 live births) but 
are responsible for 13% of neonatal intensive care unit (NICU) admissions and up to a third 
of neonatal deaths.1  Although overall neonatal mortality has halved in the last decade, 
mortality rates due to congenital anomalies remain unchanged.1  Aneuploidy and copy 
number variation (detected using G-banding karyotype and chromosome microarray 
analysis (CMA)) are detected in up to 40% of pregnancies with malformations.2  In 
approximately 60% of malformations the underlying aetiology is unresolved with a 
proportion of cases being the result of monogenic disorders.3  Careful prenatal imaging is 
vital in the detection and classification of fetal structural anomalies.  It is important to 
establish whether an anomaly is isolated or if there are multiple abnormalities, as is the 
subsequent classification into malformations, deformations and disruptions.  This is helpful 
in formulating a clinical risk of a monogenic aetiology and aids the selection of further 
investigations.  Traditionally, genomic testing (either pre- or postnatally) has been based 
upon the use of ‘targeted’ gene tests and has been limited by incomplete phenotypic 
information and false negative diagnosis if a variant gene is not represented in the selected 
panel of tests.  Through the application of genomic databases cataloguing prenatal findings 
with confirmatory postnatal diagnosis to complement the results of next generation 
sequencing (NGS), perinatal prognostic information for the purpose of counselling will 
improve.  
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CURRENT PERINATAL ANOMALY INVESTIGATION 
A primary malformation is a structural defect in an organ that can be traced back to its 
embryological development, whilst a secondary malformation is interruption of the normal 
development of an organ following external influences.2  This review focuses upon those 
malformations which result from a genetic aetiology.  The presence of single or multiple 
anomalies, identified by systematic prenatal imaging and postnatal examination,2,4  is 
associated with a genetic or chromosomal aetiology in up to 40% of cases, which, if 
diagnosed prenatally, can aid in counselling with regard to long-term prognosis by a multi-
disciplinary team.2  
   
 Review by a clinical geneticist either prenatally or postnatally, who after family pedigree 
analysis and clinical examination may instigate targeted gene testing, which typically 
involves serial sequencing of single genes or gene panels to explore a potential molecular 
genetic diagnosis.  This is time consuming, relying on a narrow differential diagnosis, and 
choosing a specific test to identify a pathologic variant.  The examination of the whole 
exome (ES) and genome (WGS) by NGS may be a potentially valuable tool in both prenatal 
and postnatal investigation of a unifying molecular diagnosis.   
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NEXT GENERATION SEQUENCING 
NGS can interrogate the human genome down to the level of one base pair through either; 
(i) ES assessing all 20,000 gene coding regions (responsible for 85% of disease-causing 
variants), or by; (ii) WGS assessing the entire genome including introns, non-coding RNA and 
mitochondrial DNA in addition to assessment of copy number variation and structural 
rearrangements.5  In perinatology, there is growing evidence from several ‘proof of concept’ 
studies (e.g. Prenatal Assessment of Genomes and Exomes (PAGE) study and the UK 
Nationwide 100,000 Genomes Project) suggesting that there is a significant additional  
molecular diagnostic rate through introducing NGS into mainstream clinical practice while 
simultaneously serving as translational studies with a proposed up and running framework 
for ES.6,7   It is anticipated that through NGS, the rate of diagnosis of monogenic disorders 
presenting with congenital anomalies will increase, as will our understanding as to why such 
anomalies arise during development, bringing us a step further to possible prevention.8 
  
Prenatal next generation sequencing 
The PAGE study is the largest prospective, prenatal study to date (Lancet 2019, In press), 
assessing the clinical utility of ES in investigation of the malformed fetus.  So far, 610 trios 
(fetus and both parents) have been analysed in cases where fetal structural anomalies have 
been identified using ultrasound and where autosomal/sex aneuploidy and large copy 
number variants have been excluded.6  This prospective study demonstrated that prenatal 
ES provides up to a 8.5% additional diagnostic yield of pathological variants when compared 
to conventional genetic testing.6  Another smaller prospective prenatal series conducted by 
Columbia University (Lancet 2019, In press) demonstrated similar findings with a diagnostic 
yield of 10.3% (n=234 trios).9   The differences in detection rates between studies may have 
been secondary to variation in interpretational approaches; with the PAGE study utilising a 
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virtual panel of 1,628 genes (from the Deciphering Developmental Disorders study) 10 and 
the Columbia study including all genes.  This resulted in 0.42 variants requiring manual 
interpretation per case in PAGE versus 4.8 variants per case in the Columbia Study, 
demonstrating the challenge of balancing increased interpretational burden with increased 
sensitivity.  The PAGE study also noted that the pathologic variant rate varied according to 
the anatomical anomaly identified and whether these were isolated or multiple [Figure 1].  A 
relatively low rate (4%) of variants of uncertain significance (VUS) was described.6  Only if 
the ‘variant’ was considered causative was it fed back to parents after the end of the 
pregnancy.  The PAGE study is unique as it assessed the application of ES in a relatively 
unselected population (as opposed to ES being performed following clinical genetic 
consultation) and the cohort included a heterogeneous mix of congenital anomalies (from 
increased nuchal translucency (>4mm) to multiple structural anomalies).  The relatively low 
diagnostic yield in the PAGE study is at variance with paediatric series where complex 
investigation and phenotyping is feasible as opposed to reliance upon relatively subjective 
prenatal ultrasound findings.11 The use of trio (parental) analysis as opposed to proband 
(fetus) only, enriched the variant interpretation process and the study unmasked the 
challenges posed by ethical issues such as identification and uncertainty of VUS, and the 
importance of informed consent and parental counselling (both pre- and post-test).  In 
addition, this study will elucidate the contribution of different forms of genetic variation in 
prenatal structural anomalies and determine the cost-effectiveness of prenatal WES 
potentially catalysing the clinical adoption of this technology by in the UK.12  
 
Next generation sequencing in the critically ill neonate 
Exome sequencing is more established in the postnatal setting.  This is demonstrated by the 
significant increase in the number of monogenic disorders which are now identifiable in the 
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new-born period.1  Many genetic conditions present within the first 28-days of life, often 
resulting in a critically ill neonate where the cause is not clearly identifiable using standard 
investigations.3  Onset progression of such monogenic disorders tends to be rapid in 
neonates and there is insufficient time for serial screening of a selection of the thousands of 
known single gene disorders using standard methods.  Additionally, variable phenotypes and 
neonates which may ‘grow into’ their diagnoses mean that assessment is challenging and 
phenotyping may not clearly identify the primary pattern of disease.  Hence it is unsurprising 
that current research is focusing on the feasibility of introducing rapid NGS technologies into 
the NICU setting.13  When applied to critically ill infants in the NICU and intensive care 
setting, NGS results can be obtained in 50 hours,13 achieving a molecular diagnosis in up to 
37% of subjects and subsequently affecting clinical decision making (i.e. redirecting care, 
considering new subspecialist care, and medication/dietary modifications) in over half of 
cases.3  Future introduction of NGS has the potential to be highly cost-effective by reducing 
mortality and length of hospital stay as well as bypassing the prolonged course of 
investigation such neonates would likely face through childhood.13   
 
In older infants and children, NGS has been shown to be beneficial in the understanding and 
management of congenital diarrhoeas and enteropathies14 as well as those with unexplained 
seizures and neurodevelopmental delay, where a preponderance for autosomal dominant 
de novo pathogenic variants is commonly seen, which can be discovered using ES.15  There 
have been several prospective large scale studies assessing the clinical utility of ES in 
children with suspected monogenic disorders, in whom the definitive diagnosis is often 
significantly delayed.  The yield in this group is between 25-52% dependent on the group 
assessed, being greater in the dysmorphic child with a suspected heterogeneous disorder or 
overlapping disorders as opposed to one with an isolated intellectual disability.3,16  Once 
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again, ES has been shown to lead to a significant alteration in management and improved 
long-term outcomes, in addition to offering prenatal genetic diagnosis in subsequent 
pregnancies once a mutation has been identified.3,13,17 Such studies support referral by 
paediatricians to a genetic service offering NGS early in the diagnostic stage.  Appropriate 
counselling is vital to inform parents of the potential to uncover a pathogenic variant 
through future re-analysis.  This has been demonstrated by the Deciphering Developmental 
Disorders research consortium where, through contemporary re-analysis of 1,333 trios in 
children with an undiagnosed developmental disorder, by applying updated bioinformatics 
pipelines and variant calling systems, the diagnostic yield increased over time from from 
27% up to to 40%.10   
 
In relation to WGS in children with suspected disease of Mendelian inheritance, an 
additional diagnostic yield compared to ES alone of 8.7% has been proposed, although 
potential pitfalls include challenges with variant interpretation.18  The main advantage of 
WGS is it’s potential use as an ‘all-in-one’ genetic test combining copy number variation, 
structural rearrangements and single base pair changes, in addition to assessment of 
intronic and epigenetic regions.    
 
Next generation sequencing in perinatal autopsy 
NGS also has the potential to extend the clinical perinatal autopsy examination, for example 
through use of ES in infants with suspected sudden death due primarily to cardiac 
arrhythmias.19  There are limited studies which have assessed use of NGS use in the perinatal 
post-mortem setting, although the scope for added genetic variant diagnostic yield is 
potentially huge.20  In a sub-cohort of the PAGE study 27 trios involving fetuses with 
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significant congenital anomalies identified prenatally that had undergone autopsy were 
retrospectively assessed.  In this cohort, WES provided an additional diagnostic yield of 
pathogenic variants in 37% of cases compared with standard investigation [Figure 1].20  The 
possible reason for a higher diagnostic yield in fetuses undergoing post-mortem examination 
was secondary to improved identification of anomalies (including subtle dysmorphology) 
and a trend to a larger proportion of probands with multiple anomalies.  As we become 
increasingly aware of the strong association of single gene disorders with congenital 
anomalies and perinatal death, it is vital that even where NGS is not currently offered, snap 
frozen samples of fetal tissue should be obtained so that DNA is available for future 
analysis.21 However, extracting high quality DNA is less successful from post-mortem tissue 
than that from living tissue.22  The added clinical utility of WGS has yet to be assessed in 
perinatal post-mortem.12  
 
Clinical considerations with Next Generation Sequencing 
1. Multidisciplinary team - The potential benefit of NGS in both the pre- and post-natal 
setting, highlights the need for comprehensive perinatal MDTs, incorporating clinical 
pathologists, genomic scientists, geneticists, neonatologists and fetal medicine sub-
specialists to assist with variant interpretation and pre and post-test counselling.23    
2. Pre- and post-test counselling – Parents must be given accurate information before 
deciding on proceeding with NGS testing.23    They must be aware that testing is optional and 
that a clear, definitive diagnosis may not obtained and test turnaround time (TAT) can be of 
variable duration.23 It is important that parents understand the challenges and complexity of 
variant interpretation and the levels of potential uncertainty, which may arise from this 
process.  The possibility of secondary or incidental findings must also be discussed in 
addition to potential ethical issues that may arise.  In the fetus and neonate this is most 
notable as there is the potential for unveiling a significant secondary results such as an 
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increased risk of subsequent adult-onset disease.  In the PAGE study such ‘variants’ were not 
screened for but a more liberal bioinformatic screening process could identify such 
anomalies. A further challenge is to explain that the field of NGS is evolving, as are the 
pathologic variant lists (if utilised).  As these variant lists are updated over time with the 
addition of new pathologic variants (and their associated phenotypes) identified, a proband 
(fetus/newborn) in whom no variant was found on initial testing may have a significant 
finding identified on future re-testing.23  Therefore detailed informed, written consent 
should be obtained prior to testing.24 For parents making decisions about pregnancy 
continuation, the level of potential uncertainty posed by ES is challenging as one is 
attempting to predict the phenotype of a child which has not yet been born and parents are 
expected to make autonomous decisions based upon this information.  Despite the complex 
and sometimes non-definitive nature of the information to be relayed the health profession 
must not be tempted adopt a paternalistic approach and must fully inform patients to 
obtain consent prior to testing.23   Studies assessing the views of health care professionals 
regarding ES have unveiled concerns from, notably Obstetricians who felt that “next 
generation testing could lead to increased levels of parental anxiety”.25 This again highlights 
the need for education of all health care professionals and the need for a multidisciplinary 
team approach to counselling.25   As noted by the PAGE study,6 before ES is rolled out into 
clinical care, there needs to be a consensus on the development of a good model of ethical 
practice exploring parental expectations, counselling and professional duties.5 
3. Accurate phenotyping - Accurate variant interpretation requires detailed phenotyping 
with classification using systems such as Human Phenotype Ontology.21  This allows targeted 
enrichment or application of a clinical exome panel to be selected to optimise coverage of 
areas of the genome known to be associated with system anomaly subtypes.  The clinical 
exome panel provides a more efficient approach than exome sequencing, increasing the 
need for accurate phenotyping.  A multi-disciplinary approach is required to obtain a so-
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called ‘deep phenotype’ prior to consideration of performing NGS.  Additionally the 
application of clinical variant databases (although not specific to the fetus) such as Clinvar 
and DECIPHER may aid in phenotype matching and variant interpretation, and similarly any 
novel variants discovered should be reported to such database consortiums in addition to 
phenotype data. 6,23,26  Instances where phenotyping has been adequately obtained has been 
shown to optimise the diagnostic yield from ES, notably in cases of prenatally suspected 
skeletal dysplasias or in perinatal autopsy.20,27 
4. Recommendations – Recent guidance from the American College of Obstetricians and 
Gynaecologists and a Joint Statement from International Society of Prenatal Diagnosis, 
Society of Maternal Fetal Medicine and Perinatal Quality Foundation does not recommend 
routine use of ES in the prenatal setting, but acknowledges that there are circumstances 
where it may be considered following liaison with an expert.28,29 A recent publication from 
the UK Nuffield Council on Bioethics acknowledged the potential benefit of using NGS to 
improve the care and treatment of seriously ill babies but warned against the its use in 
widespread screening in otherwise healthy babies.30 
 
 
Technical considerations with Next Generation Sequencing 
A sample pathway for performing NGS is demonstrated in Figure 2.  While a detailed 
technical description of the process of NGS is beyond the scope of this review it is based 
upon the principle of massive parallel sequencing with subsequent alignment to the human 
reference genome and identification of variants.5    There are several challenges with regards 
clinical implementation of NGS which are considered below: 
1. Trio analysis – In order to determine heritability and to aid in variant interpretation and 
reporting, It is recommended that DNA is obtained not only from the affected proband but 
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also from both biological parents, as has been the case in the majority of NGS studies 
assessing for single gene disorders.6-8 The majority of mutations identified in congenital 
anomalies are of an autosomal dominant de novo nature, hence parental samples are 
important in defining this inheritance pattern.23  There is emerging evidence that in the 
absence of sufficient proband DNA, where a lethal autosomal recessive disorder is 
suspected, sequencing of parental samples can still be performed to diagnose single gene 
disorders.31 
2. Variant interpretation – Following massive parallel sequencing of the DNA, bioinformatic 
pipelines are required to align and annotate reads and interpret variants graded using a five 
class system raging from benign to pathogenic.  Most notable in the prenatal setting, variant 
interpretation is the most time-consuming and costly stage of the ES process as there are 
currently no variant databases specific to the fetus to aid interpretation, nor are there 
recognised guidelines.  Interpretation relies upon the skill mix and experience of the 
multidisciplinary clinical review panel which are vital, to form a consensus in relation to 
variant pathogenicity and reporting.  Investigation and decision-making with regards variant 
grading can be cumbersome, requiring an adjunctive literature review and research for each 
potentially pathogenic variant. 25,28,32,33  
3. Validation – Current practice and the majority of NGS research studies validate 
pathogenic variants using Sanger sequencing or an alternative technique.34 
4. Turn-around-time – In the prenatal setting particularly, fast TAT is vital so that couples 
can make autonomous decisions about pregnancy management.  Since the advent of NGS, 
the TAT has traditionally been protracted and in the PAGE study pathogenic variants were 
only fed back post-natally.6  Recent studies utilising ES in the prenatal setting have reported 
much faster TAT of two to three weeks.23,35  With the application of more accurate 
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phenotyping and targeted bioinformatics pipelines it is likely that as experience with 
prenatal NGS increases, TAT will reduce significantly. 23,25 
 
 
Benefits and Risks of Next Generation Sequencing 
The risks benefits of the perinatal application of NGS are summarised in Table 1.  
 
Future considerations 
There is a significant amount of the human genome, that we do not yet fully understand, 
and much of the pathology underpinning congenital anomalies are suspected to lie within 
the intronic regions of the genome, where regulators such as the transcriptome and 
methylome control gene expression.36  While WGS may go some way in assessing genetic 
variation in these regions, clinical studies thus far demonstrate a limited additional benefit 
over ES.18 Figure 3 demonstrates the proposed the pathological weight of causes of 
congenital anomalies and what is yet to be discovered.  The future of perinatology will likely 
see a move toward a WGS approach with the use of non-invasive analysis of free-fetal DNA 
in the maternal circulation or NGS performed on parental samples only, without the need 
for proband DNA.36 
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CONCLUSION 
Next generation sequencing is proving to be a valuable diagnostic tool in the setting of 
perinatal congenital anomaly and suspected genetic disease.  The data produced from 
prospective studies assessing its utility are reproducible and are a major step in relation to 
translation of NGS into routine perinatal clinical practice in order to obtain a unifying 
molecular diagnosis.  Clinical, technical and ethical concerns must be thoroughly addressed 
through clinical guidelines before NGS is introduced into the perinatal setting.   One must 
acknowledge the blind spots, which ES alone can leave in relation to detection of copy 
number variants and balanced chromosomal anomalies and consider combination testing 
with existing methods or eventual transition into WGS.  Accurate phenotyping of congenital 
anomalies from the outset with appropriate target enrichment or clinical exome selection is 
the most vital stepping-stone to establishing a diagnosis.  Through the application of NGS we 
can not only diagnose but also underpin the underlying aetiology of congenital anomalies, 
which will facilitate the development of future treatments and preventative therapies.  
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Advantages Challenges 
Additional diagnostic yield  
Ends ‘diagnostic odyssey’ 
Technical 
 Coverage – Incomplete exon capture, GC rich regions 
 Sample processing (MCC and DNA quality/quantity) 
 Does not assess whole genome 
 Validation with Sanger sequencing 
 Accurate phenotyping 
Provides information on 
prognosis 
Service provision 
 Pre and post-test counselling 
 Education of workforce 
 Need for increased resources 
Gene discovery Interpretational 
 Variant interpretation 
 Bioinformatic pipelines 
 Variants of unknown significance 
 Secondary or incidental findings 
 False negatives 
Facilitates counselling for 
recurrence risk 
Ethical 
 Non paternity or consanguinity 
 Parental expectations 
 Limiting child’s ‘open future’ 
 Data ownership 
 Implications for wider family 
 Reanalysis and reporting 
 Diversity in society 
Automated High cost 
Multiplexed Turnaround time 
Can be extended to NIPD Lack of international guidelines 
 
Table 1 – Advantages and challenges of next generation sequencing 
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FIGURE LEGENDS 
1. Percentage diagnostic yield of exome sequencing pre- and postnatally per system  
2. Pathway for next generation sequencing 
3. Proportion of anomalies diagnosed using existing genomic technologies (CMA = 
Chromosome microarray; ES = Exome sequencing; WGS = Whole genome 
sequencing) 
 
 
 
 
